These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 8103770)

  • 21. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS; Scanlon MF; Peters JR
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of potentiation of cholinergic tone by pyridostigmine on the GH response to GHRH in elderly men.
    Coiro V; Volpi R; Bertoni P; Finzi G; Marcato A; Caiazza A; Colla R; Giacalone G; Rossi G; Chiodera P
    Gerontology; 1992; 38(4):217-22. PubMed ID: 1358762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.
    Ghigo E; Bellone J; Aimaretti G; Bellone S; Loche S; Cappa M; Bartolotta E; Dammacco F; Camanni F
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3323-7. PubMed ID: 8784091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
    Mota A; Bento A; Peñalva A; Pombo M; Dieguez C
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic modulation of growth hormone responses to growth hormone-releasing hormone in uraemic patients on peritoneal dialysis.
    Díez JJ; Iglesias P; Selgas R; Bajo MA; Aguilera A
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):587-93. PubMed ID: 11106919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E; Goffi S; Arvat E; Nicolosi M; Procopio M; Bellone J; Imperiale E; Mazza E; Baracchi G; Camanni F
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
    Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children.
    Bellone J; Ghigo E; Procopio M; Arvat E; Valente F; Boffano GM; Maccario M; Dentelli P; Camanni F
    Panminerva Med; 1993 Mar; 35(1):1-4. PubMed ID: 8316397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients.
    Giustina A; Bossoni S; Bodini C; Cimino A; Pizzocolo G; Schettino M; Wehrenberg WB
    Acta Endocrinol (Copenh); 1991 Nov; 125(5):510-7. PubMed ID: 1759540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
    Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha 2-adrenergic agonism enhances the growth hormone (GH) response to GH-releasing hormone through an inhibition of hypothalamic somatostatin release in normal men.
    Devesa J; Arce V; Lois N; Tresguerres JA; Lima L
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1581-8. PubMed ID: 1977761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
    Borges MH; Castro RC; Kater CE; Lengyel AM
    Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis of growth hormone (GH) deficiency in adults with hypothalamic-pituitary disorders: comparison of test results using pyridostigmine plus GH-releasing hormone (GHRH), clonidine plus GHRH, and insulin-induced hypoglycemia as GH secretagogues.
    Hoeck HC; Vestergaard P; Jakobsen PE; Falhof J; Laurberg P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1467-72. PubMed ID: 10770183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the morphological evaluation of the pituitary and the growth hormone (GH) response to GH-releasing hormone Plus arginine in children and adults with congenital hypopituitarism.
    Maghnie M; Salati B; Bianchi S; Rallo M; Tinelli C; Autelli M; Aimaretti G; Ghigo E
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1574-9. PubMed ID: 11297586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.